The competition to address two areas of huge unmet medical need is heating up, and Eli Lilly (NYSE: LLY) has a chance of being the leader in both.
Following a set of encouraging second-quarter 2023 financial results, Lilly stock rose more than a tenth on Tuesday, a remarkable jump for such a large company.
The excitement reflects confidence in the firm’s new Alzheimer’s candidate and a potential weight loss treatment, Mounjaro (tirzepatide), which took in $978 million sales in the quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze